Insider Selling: P3 Health Partners (NASDAQ:PIII) Major Shareholder Sells $824,000.00 in Stock

P3 Health Partners Inc. (NASDAQ:PIII) major shareholder Hudson Vegas Investment Spv, L sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $16.48, for a total transaction of $824,000.00. Following the sale, the insider directly owned 48,959 shares in the company, valued at approximately $806,844.32. The trade was a 50.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

P3 Health Partners Stock Down 2.4%

Shares of PIII stock opened at $10.69 on Friday. P3 Health Partners Inc. has a 52 week low of $1.52 and a 52 week high of $16.89. The stock has a market capitalization of $77.61 million, a PE ratio of -0.32 and a beta of 1.63. The firm has a 50 day moving average of $10.98 and a two-hundred day moving average of $6.62.

P3 Health Partners (NASDAQ:PIII) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($1.89) by $1.26. The business had revenue of $386.38 million during the quarter, compared to analyst estimates of $377.80 million.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on PIII. Wall Street Zen upgraded P3 Health Partners to a “hold” rating in a report on Saturday, July 4th. Weiss Ratings upgraded P3 Health Partners from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 28th. TD Cowen reissued a “hold” rating and set a $14.00 price objective (up from $3.00) on shares of P3 Health Partners in a research report on Friday, May 22nd. UBS Group set a $14.00 price objective on P3 Health Partners in a research report on Friday, May 15th. Finally, Lake Street Capital reaffirmed a “buy” rating and issued a $23.00 target price on shares of P3 Health Partners in a report on Tuesday. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, P3 Health Partners has a consensus rating of “Hold” and an average target price of $17.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in P3 Health Partners stock. Diversified Trust Co acquired a new stake in P3 Health Partners Inc. (NASDAQ:PIII) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 20,316 shares of the company’s stock, valued at approximately $63,000. Diversified Trust Co owned about 0.28% of P3 Health Partners at the end of the most recent quarter. Hedge funds and other institutional investors own 7.75% of the company’s stock.

About P3 Health Partners

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.